The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(12), С. 764 - 783

Опубликована: Авг. 15, 2023

Язык: Английский

---

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2023, Номер 8(2), С. 179 - 191

Опубликована: Янв. 5, 2023

Язык: Английский

---

FXR agonists in NASH treatment

Journal of Hepatology, Год журнала: 2023, Номер 79(5), С. 1317 - 1331

Опубликована: Авг. 9, 2023

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear highly expressed in the liver and intestine, regulates expression of genes involved cholesterol homeostasis, hepatic gluconeogenesis, lipogenesis, inflammation fibrosis, addition to controlling intestinal barrier integrity, preventing bacterial translocation maintaining gut microbiota eubiosis. Non-alcoholic steatohepatitis (NASH), an advanced stage non-alcoholic fatty disease, is characterized by steatosis, hepatocyte damage (ballooning) inflammation, leading cirrhosis hepatocellular carcinoma. NASH represents major unmet medical need, but no pharmacological treatments have yet been approved. pleiotropic mechanisms development offer range therapeutic opportunities among them FXR activation has emerged as established target. Various agonists with different physicochemical properties, which can be broadly classified BA derivatives, non-BA-derived steroidal agonists, non-steroidal partial are clinical development. In this review we will summarize key preclinical features most critically evaluate their potential treatment.

Язык: Английский

---

Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy

Seminars in Cancer Biology, Год журнала: 2023, Номер 93, С. 20 - 35

Опубликована: Май 4, 2023

Язык: Английский

---

NASH drug treatment development: challenges and lessons

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2023, Номер 8(10), С. 943 - 954

Опубликована: Авг. 16, 2023

Язык: Английский

---

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Metabolism, Год журнала: 2023, Номер 146, С. 155642 - 155642

Опубликована: Июнь 26, 2023

Язык: Английский

---

Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa

Liver International, Год журнала: 2024, Номер 44(4), С. 1061 - 1070

Опубликована: Фев. 2, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in general population among patients T2D Middle East North Africa (MENA) region.

Язык: Английский

---

Assessing the Efficacy of Farnesoid X Receptor Agonists in the Management of Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis

Clinics and Research in Hepatology and Gastroenterology, Год журнала: 2025, Номер unknown, С. 102530 - 102530

Опубликована: Янв. 1, 2025

Язык: Английский

---

NAFLD, MAFLD and obesity: brothers in arms?

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2022, Номер 20(2), С. 67 - 68

Опубликована: Дек. 5, 2022

Язык: Английский

---

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

Current Obesity Reports, Год журнала: 2023, Номер 12(3), С. 191 - 206

Опубликована: Июль 5, 2023

To summarize experimental and clinical evidence on the association between tumor necrosis factor-α (TNF-α) nonalcoholic fatty liver disease (NAFLD) discuss potential treatment considerations.Experimental suggests that TNF-α is a cytokine with critical role in pathogenesis of NAFLD. Although, production may be an early event during course (NAFL), play more substantial steatohepatitis (NASH) NAFLD-associated fibrosis. Moreover, potentiate hepatic insulin resistance, thus interconnecting inflammatory metabolic signals possibly contributing to development NAFLD-related comorbidities, including cardiovascular disease, hepatocellular carcinoma, extra-hepatic malignancies. In terms, probably associated severity NAFLD; circulating gradually increases from controls patients NAFL, then, NASH. Given this association, various therapeutic interventions (obeticholic acid, peroxisome proliferator-activated receptors, sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, probiotics, synbiotics, rifaximin, vitamin E, pentoxifylline, ursodeoxycholic fibroblast growth factor-21, n-3 polyunsaturated acids, statins, angiotensin blockers) have been evaluated for their effect Interestingly, anti-TNF biologics shown favorable effects, which open possible window management advanced The key pathogenic NAFLD warrants further investigation important diagnostic implications.

Язык: Английский

---